EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Adam D Cohen iD, María-Victoria Mateos iD, Yael C Cohen, Paula Rodriguez-Otero iD, Bruno Paiva iD, Niels W C J van de Donk, Thomas Martin, Attaya Suvannasankha iD, Kevin C De Braganca iD, Christina Corsale, Jordan M Schecter, Helen Varsos und 12 weitere

Blood · 19.01.2023 · 141 (3) · 219-230

DOI: 10.1182/blood.2022015526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 19.01.2023. Verfasst von Adam D Cohen und 23 weiteren Autor:innen. Beteiligte Einrichtung: Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Multiple Myeloma, Neurotoxicity Syndromes, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 217-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B-cell maturation antigen (BCMA)–targeting therapies, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs), are promising treatments for multiple myeloma (MM), but disease may progress after their use. CARTITUDE-2 is a phase 2, multicohort study evaluating the safety and efficacy of cilta-cel, an anti-BCMA chimeric antigen receptor T therapy, in various myeloma patient populations. Patients in cohort C progressed despite treatment with a proteasome inhibitor, immunomodulatory drug, anti-CD38 antibody, and noncellular anti-BCMA immunotherapy. A single cilta-cel infusion was given after lymphodepletion. The primary end point was minimal residual disease (MRD) negativity at 10−5. Overall, 20 patients were treated (13 ADC exposed; 7 BsAb exposed; 1 in the ADC group also had prior BsAb exposure). Sixteen (80%) were refractory to prior anti-BCMA therapy. At a median follow-up of 11.3 months (range, 0.6-16.0), 7 of 20 (35%) patients were MRD negative (7 of 10 [70.0%] in the MRD-evaluable subset). Overall response rate (95% confidence interval [CI]) was 60.0% (36.1-80.9). Median duration of response and progression-free survival (95% CI) were 11.5 (7.9—not estimable) and 9.1 (1.5—not estimable) months, respectively. The most common adverse events were hematologic. Cytokine release syndrome occurred in 12 (60%) patients (all grade 1-2); 4 had immune effector cell-associated neurotoxicity syndrome (2 had grade 3-4); none had parkinsonism. Seven (35%) patients died (3 of progressive disease, 4 of adverse events [1 treatment related, 3 unrelated]). Cilta-cel induced favorable responses in patients with relapsed/refractory MM and prior exposure to anti-BCMA treatment who had exhausted other therapies. This trial was registered at www.clinicaltrials.gov as NCT04133636.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaNeurotoxicity SyndromesReceptors, Chimeric AntigenHumansImmunotherapyAntibodiesB-Cell Maturation AntigenImmunotherapy, Adoptive

Substanzen

cell-associated neurotoxicityReceptors, Chimeric AntigenAntibodiesB-Cell Maturation Antigen

Autor:innen und Institutionen

  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Hospital Clinico Universitario de Salamanca, Salamanca, Spain.
  • Tel-Aviv Sourasky (Ichilov) Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Clinica Universidad de Navarra, CCUN, Centro de Investigación, Medica Aplicada (CIMA), Instituto de Investigación, Sanitaria de Navarra (IDISNA, CIBERONC), CIBER-ONC CB16/12/00369, Pamplona, Spain.
  • Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.

ORCID-Profile: Adam D Cohen, María-Victoria Mateos, Paula Rodriguez-Otero, Bruno Paiva, Attaya Suvannasankha, Kevin C De Braganca, William Deraedt, Pankaj Mistry, Jesus San-Miguel

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Cohen, A. D., Mateos, M. V., Cohen, Y. C., Rodriguez-Otero, P., Paiva, B., van de Donk, N. W. C. J., Martin, T., Suvannasankha, A., De Braganca, K. C., Corsale, C., Schecter, J. M., Varsos, H., Deraedt, W., Wang, L., Vogel, M., Roccia, T., Xu, X., Mistry, P., Zudaire, E., …, & San-Miguel, J. (2023). Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood, 141(3), 219-230. https://doi.org/10.1182/blood.2022015526

Vancouver

Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk NWCJ, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141(3):219-230. doi:10.1182/blood.2022015526

BibTeX
@article{Cohen2023,
  author = {Cohen, Adam D and Mateos, María-Victoria and Cohen, Yael C and Rodriguez-Otero, Paula and Paiva, Bruno and van de Donk, Niels W C J and Martin, Thomas and Suvannasankha, Attaya and De Braganca, Kevin C and Corsale, Christina and Schecter, Jordan M and Varsos, Helen and Deraedt, William and Wang, Liwei and Vogel, Martin and Roccia, Tito and Xu, Xiaoying and Mistry, Pankaj and Zudaire, Enrique and Akram, Muhammad and Nesheiwat, Tonia and Pacaud, Lida and Avivi, Irit and San-Miguel, Jesus},
  title = {Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents},
  journal = {Blood},
  year = {2023},
  volume = {141},
  number = {3},
  pages = {219--230},
  doi = {10.1182/blood.2022015526}
}
Kostenlos starten →